77
Participants
Start Date
February 9, 2015
Primary Completion Date
March 7, 2017
Study Completion Date
March 22, 2018
Obeticholic Acid (OCA)
Placebo
Weill Cornell Medical College, New York
Mount Sinai Medical Center, New York
University of Rochester Medical Center, Rochester
University of Pittsburgh, Pittsburgh
University of Pennsylvania, Philadelphia
Azienda Socio Sanitaria Territoriale di Monza, Monza
Mercy Medical Center, Baltimore
Johns Hopkins University, Baltimore
McGuire DVAMC, Richmond
Gastrointestinal Specialists of Georgia, Marietta
Piedmont Atlanta Georgia Transplant Institute, Atlanta
University of Miami Hospital, Miami
Azienda Ospedaliera Universita di Padova - Struttura Operativa Complessa Gastroenterologia, Padua
Southern Therapy and Advanced Research, Jackson
Dipartimento di Universitario di Scienze Mediche e Chirurgiche, Bologna
University of Louisville, Louisville
The Ohio State University Wexner Medical Center, Columbus
University Hospitals Cleveland Medical Center, Cleveland
Indiana University Health University Hospital, Indianapolis
Henry Ford Health System, Detroit
Mayo Clinic, Rochester
Rush University Medical Center, Chicago
University of Chicago, Chicago
St. Louis University Gastroenterology & Hepatology, St Louis
Washington University School of Medicine, St Louis
Tulane Medical Center, New Orleans
The Liver Institute at Methodist Dallas Medical Center, Dallas
Baylor University Medical Center, Dallas
Texas Digestive Disease Consultants, Southlake
CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston
Liver Associates of Texas, P.A., Houston
University of Colorado, Denver, Aurora
St. Joseph's Hospital & Medical Center, Phoenix
Mayo Clinic, Phoenix
University of California Davis Medical Center, Sacramento
Swedish Organ Transplant and Liver Center, Seattle
Lead Sponsor
Intercept Pharmaceuticals
INDUSTRY